Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro

被引:49
作者
Drosopoulos, WC [1 ]
Prasad, VR [1 ]
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
D O I
10.1128/JVI.72.5.4224-4230.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nucleoside analog-resistant variants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) that displayed higher in vitro polymerase fidelity were previously identified via nucleotide insertion and mispair extension assays. To evaluate the contribution of increased nucleotide insertion and primer extension fidelities on the overall error rate of HIV-1 RT, we have measured the impact of two such mutations, E89G and M184V, on DNA copying fidelity in an M13 phage-based forward mutation assay. Using this assay, we observed mutation frequencies of 8.60 x 10(-3), 6.26 x 10(-3), 5.53 x 10(-3), and 12.30 x 10(-3) for wild-type, E89G, M184V, and double-mutant E89G/M184V HIV-1 RTs, respectively. Therefore, the overall polymerase fidelities of wild-type, E89G, M184V, and E89G/M184V HIV-1 RTs are similar (less than twofold differences) for DNA-dependent DNA synthesis. Thus, rather large increases in fidelity of deoxynucleoside triphosphate insertion and mispair extension observed previously appear not to influence the overall error rate of these mutants. However, a qualitative analysis of the mutations induced revealed significant differences in the mutational spectra between the wild-type and mutant enzymes.
引用
收藏
页码:4224 / 4230
页数:7
相关论文
共 32 条
[1]   Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors [J].
Balzarini, J ;
Pelemans, H ;
Karlsson, A ;
DeClercq, E ;
Kleim, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13152-13157
[2]  
Bebenek K, 1995, METHOD ENZYMOL, V262, P217
[3]  
BEBENEK K, 1989, J BIOL CHEM, V264, P16948
[4]   SENSITIVITY OF WILD-TYPE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE TO DIDEOXYNUCLEOTIDES DEPENDS ON TEMPLATE LENGTH - THE SENSITIVITY OF DRUG-RESISTANT MUTANTS DOES NOT [J].
BOYER, PL ;
TANTILLO, C ;
JACOBOMOLINA, A ;
NANNI, RG ;
DING, JP ;
ARNOLD, E ;
HUGHES, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :4882-4886
[5]  
Coffin JM, 1996, AIDS, V10, pS75
[6]   Polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase [J].
Drosopoulos, WC ;
Prasad, VR .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4834-4838
[7]   Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase [J].
Essink, BBO ;
Back, NKT ;
Berkhout, B .
NUCLEIC ACIDS RESEARCH, 1997, 25 (16) :3212-3217
[8]   THE SAME MUTATION THAT ENCODES LOW-LEVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE CONFERS HIGH-LEVEL RESISTANCE TO THE (-) ENANTIOMER OF 2',3'-DIDEOXY-3'-THIACYTIDINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
CAMERON, J ;
CAMMACK, N ;
BOUCHER, C ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1390-1392
[9]   NOVEL MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE GENE THAT ENCODES CROSS-RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE [J].
GU, ZX ;
QING, G ;
LI, XG ;
PARNIAK, MA ;
WAINBERG, MA .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7128-7135
[10]   GENETIC-VARIATION IN HTLV-III/LAV OVER TIME IN PATIENTS WITH AIDS OR AT RISK FOR AIDS [J].
HAHN, BH ;
SHAW, GM ;
TAYLOR, ME ;
REDFIELD, RR ;
MARKHAM, PD ;
SALAHUDDIN, SZ ;
WONGSTAAL, F ;
GALLO, RC ;
PARKS, ES ;
PARKS, WP .
SCIENCE, 1986, 232 (4757) :1548-1553